HURA

Announcements

Nothing here yet

Daily updates

• TuHURA received U.S. Patent No. 12,734,168 covering delta opioid receptor antagonist applications in cancers driven by DOR-expressing MDSCs.Oct 5, 2026

FDA designations

Nothing here yet

News

• TuHURA Biosciences received FDA clearance to proceed with a clinical study of its TBS-2025 VISTA-inhibiting antibody in molecularly defined AML and other hematologic cancersSep 14, 2026
• TuHURA Biosciences submitted an IND application for TBS-2025, a VISTA-inhibiting antibody, in AML and other blood cancersJun 15, 2026
• TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 in melanomaFeb 2, 2026
• TuHURA releases Kintara's CVR as REM-001 meets primary safety endpointDec 15, 2025